On February 04, FSD Pharma Inc. (HUGE) gained a further 7.10% after hours while there was no official announcement from the company.
Friday’s regular session witnessed a below-average volume of 120.14K shares. The HUGE stock closed the regular session at $0.8310, just above its 52-week low of $0.8100. The stock while barely kept in the green with a gain of 0.48% in regular trading, added a good value after hours. Hence, HUGE was trading at $0.8900 per share after hours on Friday.
The specialty biotech pharmaceutical R&D company, FSD Pharma Inc. has a market capitalization of $32.91 million. Currently, the company has 49.42 million shares outstanding in the market.
HUGE stock Movement
During Friday’s regular session, HUGE stock brushed down to its 52-week low of $0.8100 and closed the session just above it. Since there is no official news or SEC filing, the stock seems to have gained because of the new low. It seems like the new low provided a good buying opportunity to investors. Therefore, the stock made a big stride up in the after-hours while it barely kept in the green during regular trading.
In the past five days, the stock has decreased by 5.57% while losing 18.53% year to date. Moreover, HUGE stock subtracted a value of 64.03% last year.
Launch of New Corporate Website
On January 20, the company announced the launch of its newly designed corporate website. The new website elaborately specifies HUGE’s emerging position along with its brain and inflammatory disorders’ novel treatment commitment. Furthermore, the website’s new look is very user-friendly for not only investors but also patients, researchers, and clinicians. It educates all users about the company’s unique approach for total brain health.
According to the Interim CEO, Anthony Durkacz, the company has strategically assembled a team of scientists for developing its next-gen therapeutics pipeline. Currently, the company’s lead drug candidates are Lucid-MS, Lucid-PSYCH, and FSD-PEA.
HUGE’s Other Developments
In 2022, Elanor N. Fish, Ph.D., member of HUGE’s Research & Clinical Advisory Board was appointed to the Order of Canada. The background for this appointment was her contributions to immunology along with groundbreaking studies.
The Order of Canada, the country’s highest civilian honors, was created in 1967. The Governor-General on the recommendation of the Advisory Council for the Order of Canada makes the appointments.
On January 10, the company participated in the H.C. Wainwright BioConnect Conference which was held virtually.
